<DOC>
	<DOC>NCT00765999</DOC>
	<brief_summary>The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C)</brief_summary>
	<brief_title>An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Patients must have entered study LINMD01 or LINMD31 and at minimum completed the pretreatment period or completed one of the following studies: MCP103004, MCP103005, MCP103201, MCP103202 Sexually active patients of childbearing potential agree to use birth control Females of childbearing potential must have a negative urine pregnancy test prior to dosing Lactating females must agree not to breastfeed Patient must meet protocol criteria for chronic constipation (CC) or irritable bowel syndrome with constipation (IBSC) Patient must not use protocoldefined prohibited medicine Patient is planning to receive an investigational drug at any time during the study Patient has an unresolved adverse event (AE) or a clinically significant finding on a physical examination, 12lead electrocardiogram (ECG), or clinical laboratory test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Constipation</keyword>
	<keyword>Chronic Constipation</keyword>
	<keyword>Irritable Bowel Syndrome With Constipation</keyword>
	<keyword>Linaclotide</keyword>
</DOC>